TruAlt Bioenergy financials

·FMCG & RetailChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹811cr+606.2% on Q2 FY26
Net profit
₹35.0cr−₹37.9 cr in Q2 FY26
EBITDA margin
12.5%+16.4 pts on Q2 FY26
EPS
₹4.04−₹5.37 in Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue811115+606.2%
EBITDA101−4.5—
EBITDA margin12.5%−4.0%+16.4 pts
Profit before tax47.1−49.2—
Net profit35.0−37.9—
EPS₹4.04−₹5.37—

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹811 crNet profit₹35.0 crNet margin4.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026
3,217—
32.592.3
68.458.0
1,6461,646
4,898—
2,7471,728
487290
17.7%16.8%
393204
22496.9
8.2%5.6%
₹25.78₹11.19
—−289
—−511
−800−800
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TRUALT₹375.10

TruAlt Bioenergy Limited

· FMCG & Retail
₹ CrorePeersSANSTARAEROPLANEGRMOVERCLSELAVTNPLGULPOLYBSHSLREGAALMcap ₹3,217 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization—3,216.6
- Cash, Equiv & ST Investments92.332.5
+ Minority Interest58.068.4
+ Total Debt1,645.81,645.8
Enterprise Value—4,898.2
Revenue1,727.52,746.7
EBITDA289.8486.7
Margin %16.7717.72
EBIT203.5392.9
Net Income96.9224.4
Margin %5.618.17
EPS, Adj (current shares)11.1925.78
Cash from Operations-289.3—
Capital Expenditures-510.7—
Free Cash Flow-800.0-800.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

TruAlt Bioenergy financials and key ratios

Prices at the previous close · figures from the company's filings with NSE

TruAlt Bioenergy (NSE: TRUALT) had a market capitalisation of ₹3,217 crore at the previous close (₹375.10 a share), a PE ratio of 14.6 on the last four quarters' profit and a price-to-book ratio of 1.99. In FY26 its consolidated net profit was ₹95.9 crore on revenue of ₹1,728 crore; in Q2 FY27 (July–September 2026) it was ₹34.7 crore. Its debt-to-equity ratio was 0.98 on 30 September 2026. Promoters held 71.38% of the shares on 30 September 2026.

Share price used
₹375.10 · previous close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

TruAlt Bioenergy at a glance · consolidated

Market cap
₹3,217 Crat ₹375.10 · previous close
PE ratio (last 4 quarters)
14.633.5 on FY26 profit
Price to book (PB)
1.99book value ₹188.81 a share
Debt to equity
0.98net debt ₹1,619 Cr
Promoter holding
71.38%+0.8 pts vs 30 Jun 202630 September 2026
Net worth
₹1,619 Cr+15.5% vs 30 Sep 202530 September 2026

Questions

What is the TruAlt Bioenergy PE ratio today?

TruAlt Bioenergy's PE ratio is 14.6 at the previous close (₹375.10 a share): a market capitalisation of ₹3,217 crore divided by consolidated net profit of ₹221 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹95.9 crore) it is 33.5.

What is the TruAlt Bioenergy debt to equity ratio?

TruAlt Bioenergy's debt-to-equity ratio was 0.98 on 30 September 2026: borrowings of ₹1,653 crore against total equity of ₹1,687 crore. A year earlier, on 30 September 2025, it was 1.10.

What is the TruAlt Bioenergy net worth?

TruAlt Bioenergy's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,619 crore on 30 September 2026, up 15.5% from ₹1,402 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹3,217 crore at the previous close.

What is the TruAlt Bioenergy PB ratio (price to book value)?

TruAlt Bioenergy's price-to-book (PB) ratio is 1.99 at the previous close: a market capitalisation of ₹3,217 crore divided by shareholders' equity (book value) of ₹1,619 crore on 30 September 2026. That is a book value of ₹188.81 per share against a share price of ₹375.10.

What is the TruAlt Bioenergy book value per share?

TruAlt Bioenergy's book value per share was ₹188.81 on 30 September 2026: shareholders' equity of ₹1,619 crore divided by the 8.58 crore shares in issue, up 15.5% from ₹163.44 a year earlier. The share price at the previous close was ₹375.10.

What is the TruAlt Bioenergy shareholding pattern?

On 30 September 2026, TruAlt Bioenergy's shares were held by promoters 71.38%, foreign portfolio investors (FII/FPI) 0.63%, domestic institutions (DII) 9.09% (including mutual funds at 7.11%) and retail and other non-institutional investors 18.91%.

What is the TruAlt Bioenergy market cap?

TruAlt Bioenergy's market capitalisation was ₹3,217 crore at the previous close: 8.58 crore shares at ₹375.10 each.

Is TruAlt Bioenergy debt free?

No. TruAlt Bioenergy had borrowings of ₹1,653 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.98. Its cash and current investments were ₹34 crore, so its net debt was ₹1,619 crore.

What is the TruAlt Bioenergy EPS?

TruAlt Bioenergy's basic earnings per share (EPS) were ₹12.30 in FY26. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹25.77.

What is the TruAlt Bioenergy promoter holding?

Promoters held 71.38% of TruAlt Bioenergy on 30 September 2026, up 0.83 percentage points from 70.55% the previous quarter, according to the shareholding pattern filed with NSE.

What is the TruAlt Bioenergy free cash flow?

In FY26, TruAlt Bioenergy generated ₹289 crore of cash from operations and spent ₹511 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹800 crore.

What is the TruAlt Bioenergy revenue and profit in FY26?

In FY26 (April 2025–March 2026), TruAlt Bioenergy's consolidated net profit was ₹95.9 crore, on revenue from operations of ₹1,728 crore.

What are the TruAlt Bioenergy latest quarterly results?

TruAlt Bioenergy's latest results are for Q2 FY27 (July–September 2026), filed on 23 October 2026: consolidated net profit ₹34.7 crore, against a loss of ₹37.9 crore in Q2 FY26; revenue from operations ₹811 crore, up 606.2% year on year.

When are the TruAlt Bioenergy next results?

TruAlt Bioenergy has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does TruAlt Bioenergy compare with its peers?

On FY26 consolidated figures, against Sanstar, Amir Chand Jagdish Kumar (Exports) and GRM Overseas: TruAlt Bioenergy's operating margin of 11.8% is the highest of the four (Sanstar 3.6%, Amir Chand Jagdish Kumar (Exports) 9.6%, GRM Overseas 4.9%; peer average 6.0%).

TruAlt Bioenergy vs Sanstar: how do they compare?

In FY26, TruAlt Bioenergy earned net profit of ₹95.9 crore on revenue of ₹1,728 crore, against ₹34.5 crore on ₹785 crore for Sanstar. TruAlt Bioenergy's operating margin was 11.8% (Sanstar 3.6%).

Where do these TruAlt Bioenergy figures come from?

From TruAlt Bioenergy's own consolidated results, balance sheets and shareholding patterns filed with NSE. Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.